

Title (en)
ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO TRAIL RECEPTORS

Title (de)
AN TRAIL-REZEPTOREN IMMUNSPECIFISCH BINDENDE ANTIKÖRPER

Title (fr)
ANTICORPS SE LIANT DE MANIERE IMMUNOSPECIFIQUE A DES RECEPTEURS DE TRAIL

Publication
EP 1572874 A4 20060531 (EN)

Application
EP 02736661 A 20020507

Priority

- US 0214268 W 20020507
- US 29347301 P 20010525
- US 29498101 P 20010604
- US 30917601 P 20010802
- US 32380701 P 20010921
- US 32736401 P 20011009
- US 33104401 P 20011107
- US 33131001 P 20011114
- US 34123701 P 20011220
- US 36986002 P 20020405

Abstract (en)
[origin: WO02097033A2] The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors, and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating, or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.

IPC 1-7
C07K 16/00; C12N 5/12; A61P 35/00; A61P 31/18; A61P 43/00; A61K 39/42; A61K 39/395

IPC 8 full level
A61K 31/00 (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 45/06** (2006.01); **A61P 1/00** (2006.01); **A61P 1/18** (2006.01); **A61P 11/00** (2006.01); **A61P 15/00** (2006.01); **A61P 17/00** (2006.01); **A61P 25/00** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01); **A61P 37/06** (2006.01); **C07K 16/28** (2006.01); **C07K 16/30** (2006.01); **C12N 1/15** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/10** (2006.01); **G01N 33/53** (2006.01); **G01N 33/574** (2006.01)

CPC (source: EP KR US)
A61K 31/00 (2013.01 - EP US); **A61K 39/395** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 1/00** (2017.12 - EP); **A61P 1/18** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/28** (2013.01 - KR); **C07K 16/2878** (2013.01 - EP US); **C07K 16/30** (2013.01 - EP US); **A61K 2039/505** (2013.01 - EP US); **C07K 2317/565** (2013.01 - EP US); **C07K 2317/622** (2013.01 - EP US)

Citation (search report)

- [PX] WO 0202641 A1 20020110 - HUMAN GENOME SCIENCES INC [US], et al
- [XP] DOBSON CLAIRE ET AL: "Generation of human therapeutic anti-TRAIL-R1 agonistic antibodies by phage display", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002, pages 579, XP001207694, ISSN: 0197-016X
- [XP] SALCEDO THEODORA W ET AL: "TRM-1, a fully human TRAIL-R1 agonistic monoclonal antibody, displays in vitro and in vivo antitumor activity", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002, pages 856, XP001207695, ISSN: 0197-016X
- [Y] TANAKA SHINJI ET AL: "Expression and antitumor effects of TRAIL in human cholangiocarcinoma", HEPATOLOGY, vol. 32, no. 3, September 2000 (2000-09-01), pages 523 - 527, XP009063335, ISSN: 0270-9139
- [Y] WALCZAK HENNING ET AL: "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 5, no. 2, February 1999 (1999-02-01), pages 157 - 163, XP002176064, ISSN: 1078-8956
- [Y] VAUGHAN T J ET AL: "HUMAN ANTIBODIES WITH SUB-NANOMOLAR AFFINITIES ISOLATED FROM A LARGE NON-IMMUNIZED PHAGE DISPLAY LIBRARY", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 14, 1 March 1996 (1996-03-01), pages 309 - 314, XP000196144, ISSN: 1087-0156
- [Y] TRAUTH B C ET AL: "MONOCLONAL ANTIBODY-MEDIATED TUMOR REGRESSION BY INDUCTION OF APOPTOSIS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 245, no. 4915, 21 July 1989 (1989-07-21), pages 301 - 305, XP000749873, ISSN: 0036-8075
- [YP] ICHIKAWA K ET AL: "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity", NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, vol. 7, no. 8, August 2001 (2001-08-01), pages 954 - 960, XP002956334, ISSN: 1078-8956
- [T] GEORGAKIS GEORGIOS V ET AL: "Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death", BRITISH JOURNAL OF HAEMATOLOGY, vol. 130, no. 4, August 2005 (2005-08-01), pages 501 - 510, XP002357745, ISSN: 0007-1048
- [T] PUKAC L ET AL: "HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo", BRITISH JOURNAL OF CANCER, vol. 92, no. 8, April 2005 (2005-04-01), pages 1430 - 1441, XP002357744, ISSN: 0007-0920 & DATABASE Geneseq [online] 19 August 2002 (2002-08-19), "Human BLyS binding scFv SEQ ID 2037.", XP002357767, retrieved from EBI accession no. GSN:ABP46026 Database accession no. ABP46026
- See references of WO 02097033A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 02097033 A2 20021205; WO 02097033 A3 20051020; AU 2002309647 B2 20080124; AU 2002309647 C1 20080911;
CA 2446723 A1 20021205; CA 2446723 C 20140121; CN 100594935 C 20100324; CN 1635908 A 20050706; DK 1572874 T3 20131216;
EP 1572874 A2 20050914; EP 1572874 A4 20060531; EP 1572874 B1 20130918; ES 2437992 T3 20140115; HK 1075470 A1 20051216;
JP 2005515963 A 20050602; JP 2009062393 A 20090326; JP 4309758 B2 20090805; KR 100942393 B1 20100217;
KR 20040003015 A 20040107; MX PA03010747 A 20040302; NZ 529359 A 20070427; PT 1572874 E 20131211; US 2003190685 A1 20031009;
US 7064189 B2 20060620

DOCDB simple family (application)

US 0214268 W 20020507; AU 2002309647 A 20020507; CA 2446723 A 20020507; CN 02814904 A 20020507; DK 02736661 T 20020507;
EP 02736661 A 20020507; ES 02736661 T 20020507; HK 05109696 A 20051101; JP 2003500202 A 20020507; JP 2008291575 A 20081113;
KR 20037015417 A 20020507; MX PA03010747 A 20020507; NZ 52935902 A 20020507; PT 02736661 T 20020507; US 13978502 A 20020507